Medtronic launched a surgical system in the U.S. designed to immobilize the thoracic and cervical spine during complex procedures and assist surgeons with navigation.
The Infinity Occipitocervical-Upper Thoracic System features a multi-axial screw that can move 60 degrees in any direction, as well as 3.0mm and 5.5mm diameter screws for a range of patient demographics and clinical applications.
The system also includes a spectrum of implant materials and sizes, and can be paired with the company’s O-arm imaging and StealthStation navigation systems.
Medtronic announced the launch during the annual meeting of the North American Spine Society in Los Angeles, and plans to make the system available globally over the next year. The Infinity OCT System is indicated for conditions including degenerative disc disease, instability or deformity, tumors, and traumatic spinal fractures or traumatic dislocations.
Last month, Medtronic announced it would acquire the remainder of Mazor Robotics, a developer of digitally-assisted spine surgery guidance systems, and plans to merge the company with its own implants, navigation and imaging products.
The $1.6 billion deal is the culmination of a phased investment agreement between the two companies that began in 2016, and Medtronic plans to maintain Mazor’s site and team in Caesarea, Israel.
“We believe robotic-assisted procedures are the future of spine surgery, enhancing surgeons’ abilities to perform complex procedures with greater precision, consistency and control,” Geoff Martha, president of Medtronic’s Restorative Therapies Group, said at the time.
By: Conor Hale
Source: Fierce Biotech
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
